Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI…
Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient populationATLANTA , Jan.…
American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a diagnostic marker, a key…
AMAR regulatory approval will allow the Company to launch ZSmile in Israel in 2026 as a precursor to a larger…
– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising…
CEO Highlights Significant Progress Achieved & Outlines Ambitious Plans for 2026MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma,…
TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a…
Fourth quarter results represent highest quarterly revenue in Company’s historyQ4 year-over-year growth of 35% to 39% driven by sales execution…
SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader…
Evaxion adds autoimmune disease as a third disease area as it expands its therapeutic focusIn future, Evaxion’s proprietary AI-Immunology™ platform…